Ireland's Jazz Pharmaceuticals Q1 revenue beats estimates, reaffirms FY outlook

Jazz Pharmaceuticals

05/05/2026 21:46

Overview

Ireland biopharma firm's Q1 revenue rose 19% yr/yr, beating analyst expectations

Adjusted EPS for Q1 beat consensus, driven by higher product sales

Growth led by Xywav, Zepzelca, Epidiolex and new Modeyso sales

Outlook

Jazz Pharmaceuticals reaffirms 2026 revenue guidance of $4.25 bln to $4.5 bln

Company expects GAAP gross margin of 89%-90% and non-GAAP gross margin of 90%-91% for 2026

Company anticipates potential U.S. launch of zanidatamab in 1L HER2+ GEA by August 2026

Result Drivers

XYWAV DEMAND - Xywav net product sales rose 18% yr/yr to $408 mln, driven by continued physician and patient demand and 425 net patient adds

EPIDIOLEX GROWTH - Epidiolex/Epidyolex net product sales grew 15% yr/yr to $250 mln, reflecting continued strong demand

ZEPZELCA UPTAKE - Zepzelca net product sales increased 60% yr/yr to $101 mln, supported by uptake in combination use for 1LM ES-SCLC

Company press release: ID:nPrecrkQya

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$1.07 bln
$976.56 mln (14 Analysts)
Q1 Adjusted EPS
Beat
$6.34
$4.57 (14 Analysts)
Q1 EPS
$4.43
Q1 Adjusted Net Income
Beat
$419.50 mln
$289.69 mln (13 Analysts)
Q1 Net Income
$293.10 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Jazz Pharmaceuticals PLC is $227.00, about 9.1% above its May 4 closing price of $208.06

The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 7 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)